Cargando…
Use of non‐vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database
PURPOSE: We aimed to describe time‐trends in the use of NOACs among a group of ambulatory patients with nonvalvular atrial fibrillation (NVAF) in Colombia and to describe treatment patterns and user characteristics. METHODS: Using the Audifarma S.A administrative healthcare database in Colombia, we...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983923/ https://www.ncbi.nlm.nih.gov/pubmed/33063370 http://dx.doi.org/10.1002/pds.5124 |
_version_ | 1783667965260988416 |
---|---|
author | Machado‐Alba, Jorge E. Gaviria‐Mendoza, Andrés Machado‐Duque, Manuel E. Tovar‐Yepes, Carlos Ruigómez, Ana García Rodríguez, Luis Alberto |
author_facet | Machado‐Alba, Jorge E. Gaviria‐Mendoza, Andrés Machado‐Duque, Manuel E. Tovar‐Yepes, Carlos Ruigómez, Ana García Rodríguez, Luis Alberto |
author_sort | Machado‐Alba, Jorge E. |
collection | PubMed |
description | PURPOSE: We aimed to describe time‐trends in the use of NOACs among a group of ambulatory patients with nonvalvular atrial fibrillation (NVAF) in Colombia and to describe treatment patterns and user characteristics. METHODS: Using the Audifarma S.A administrative healthcare database in Colombia, we identified 10 528 patients with NVAF aged at least 18 years between July 2009 and June 2017 with a first prescription (index date) for apixaban, dabigatran or rivaroxaban (index NOAC) and followed them for at least year (max, 8.0 years, mean 2.2 years). We described patient characteristics, NOAC use over time, and the dose of the first NOAC prescription. RESULTS: A total of 2153 (20.5%) patients started on apixaban, 3089 (29.3%) on dabigatran and 5286 (50.2%) on rivaroxaban. The incidence of new users of apixaban and rivaroxaban increased over study years while for dabigatran it decreased. Mean age at the index date was: 78.5 years (apixaban), 76.5 years (dabigatran), 76.0 years (rivaroxaban). The percentage of patients started NOAC therapy on the standard dose was: apixaban 38.0%, dabigatran 30.9%, rivaroxaban 56.9%. The percentage still prescribed their index NOAC at 6 months was apixaban 44.6%, dabigatran 51.4%, rivaroxaban 52.7%. Hypertension was the most common comorbidity (>80% in each NOAC cohort). CONCLUSION: During the last decade, the incidence of NOAC use in patients with NVAF affiliated with a private healthcare regime in Colombia has markedly increased. Future studies should evaluate whether the large number of patients with NVAF starting NOAC treatment on a reduced dose are done so appropriately. |
format | Online Article Text |
id | pubmed-7983923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79839232021-03-24 Use of non‐vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database Machado‐Alba, Jorge E. Gaviria‐Mendoza, Andrés Machado‐Duque, Manuel E. Tovar‐Yepes, Carlos Ruigómez, Ana García Rodríguez, Luis Alberto Pharmacoepidemiol Drug Saf Original Report PURPOSE: We aimed to describe time‐trends in the use of NOACs among a group of ambulatory patients with nonvalvular atrial fibrillation (NVAF) in Colombia and to describe treatment patterns and user characteristics. METHODS: Using the Audifarma S.A administrative healthcare database in Colombia, we identified 10 528 patients with NVAF aged at least 18 years between July 2009 and June 2017 with a first prescription (index date) for apixaban, dabigatran or rivaroxaban (index NOAC) and followed them for at least year (max, 8.0 years, mean 2.2 years). We described patient characteristics, NOAC use over time, and the dose of the first NOAC prescription. RESULTS: A total of 2153 (20.5%) patients started on apixaban, 3089 (29.3%) on dabigatran and 5286 (50.2%) on rivaroxaban. The incidence of new users of apixaban and rivaroxaban increased over study years while for dabigatran it decreased. Mean age at the index date was: 78.5 years (apixaban), 76.5 years (dabigatran), 76.0 years (rivaroxaban). The percentage of patients started NOAC therapy on the standard dose was: apixaban 38.0%, dabigatran 30.9%, rivaroxaban 56.9%. The percentage still prescribed their index NOAC at 6 months was apixaban 44.6%, dabigatran 51.4%, rivaroxaban 52.7%. Hypertension was the most common comorbidity (>80% in each NOAC cohort). CONCLUSION: During the last decade, the incidence of NOAC use in patients with NVAF affiliated with a private healthcare regime in Colombia has markedly increased. Future studies should evaluate whether the large number of patients with NVAF starting NOAC treatment on a reduced dose are done so appropriately. John Wiley & Sons, Inc. 2020-10-15 2021-04 /pmc/articles/PMC7983923/ /pubmed/33063370 http://dx.doi.org/10.1002/pds.5124 Text en © 2020 The Authors. Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Report Machado‐Alba, Jorge E. Gaviria‐Mendoza, Andrés Machado‐Duque, Manuel E. Tovar‐Yepes, Carlos Ruigómez, Ana García Rodríguez, Luis Alberto Use of non‐vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database |
title | Use of non‐vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database |
title_full | Use of non‐vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database |
title_fullStr | Use of non‐vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database |
title_full_unstemmed | Use of non‐vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database |
title_short | Use of non‐vitamin K antagonist oral anticoagulants in Colombia: A descriptive study using a national administrative healthcare database |
title_sort | use of non‐vitamin k antagonist oral anticoagulants in colombia: a descriptive study using a national administrative healthcare database |
topic | Original Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983923/ https://www.ncbi.nlm.nih.gov/pubmed/33063370 http://dx.doi.org/10.1002/pds.5124 |
work_keys_str_mv | AT machadoalbajorgee useofnonvitaminkantagonistoralanticoagulantsincolombiaadescriptivestudyusinganationaladministrativehealthcaredatabase AT gaviriamendozaandres useofnonvitaminkantagonistoralanticoagulantsincolombiaadescriptivestudyusinganationaladministrativehealthcaredatabase AT machadoduquemanuele useofnonvitaminkantagonistoralanticoagulantsincolombiaadescriptivestudyusinganationaladministrativehealthcaredatabase AT tovaryepescarlos useofnonvitaminkantagonistoralanticoagulantsincolombiaadescriptivestudyusinganationaladministrativehealthcaredatabase AT ruigomezana useofnonvitaminkantagonistoralanticoagulantsincolombiaadescriptivestudyusinganationaladministrativehealthcaredatabase AT garciarodriguezluisalberto useofnonvitaminkantagonistoralanticoagulantsincolombiaadescriptivestudyusinganationaladministrativehealthcaredatabase |